ProKidney Corp: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über ProKidney Corp Unternehmen

ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).

ProKidney Corp Informationen



BörsenkürzelPROK

Name des UnternehmensProKidney Corp

IPO-datumJun 30, 2021

CEODr. Bruce Culleton, M.D.

Anzahl der mitarbeiter204

WertpapierartOrdinary Share

GeschäftsjahresendeJun 30

Addresse2000 Frontis Plaza Blvd.

StadtWINSTON-SALEM

BörseNASDAQ Capital Market Consolidated

LandUnited States of America

Postleitzahl27103

Telefon13369997028

Websitehttps://prokidney.com/

BörsenkürzelPROK

IPO-datumJun 30, 2021

CEODr. Bruce Culleton, M.D.

Führungskräfte von ProKidney Corp



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Bruce Culleton, M.D.

Chief Executive Officer, Director

1.54M

--

Mr. Ethan Holdaway

Investor Relations

--

Mr. William F. (Bill) Doyle

Independent Director

--

Mr. Pablo Legorreta

Chairman of the Board

--

Dr. Uma Sinha, Ph.D.

Independent Director

--

Mr. James Coulston, CPA

Chief Financial Officer

--

Ms. Jennifer Fox

Independent Director

--

Dr. Alan M. Lotvin, M.D.

Independent Director

--

Dr. Darin J. Weber, Ph.D.

Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial

--

Dr. Brian J. G. Pereira, M.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Bruce Culleton, M.D.

Chief Executive Officer, Director

1.54M

--

Mr. Ethan Holdaway

Investor Relations

--

Mr. William F. (Bill) Doyle

Independent Director

--

Mr. Pablo Legorreta

Chairman of the Board

--

Dr. Uma Sinha, Ph.D.

Independent Director

--

Mr. James Coulston, CPA

Chief Financial Officer

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Sat, Nov 8

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Tolerantia LLC

16.75%

Suvretta Capital Management, LLC

9.14%

Control Empresarial de Capitales, S.A. de C.V.

7.94%

Morgan Stanley Investment Management Inc. (US)

4.23%

BlackRock Mexico Operadora SA de CV SOFI

2.54%

Andere

59.39%

Aktionäre

Anteil

Tolerantia LLC

16.75%

Suvretta Capital Management, LLC

9.14%

Control Empresarial de Capitales, S.A. de C.V.

7.94%

Morgan Stanley Investment Management Inc. (US)

4.23%

BlackRock Mexico Operadora SA de CV SOFI

2.54%

Andere

59.39%

Aktionärstypen

Aktionäre

Anteil

Corporation

24.70%

Hedge Fund

10.27%

Investment Advisor

10.23%

Investment Advisor/Hedge Fund

5.98%

Research Firm

2.84%

Individual Investor

1.92%

Endowment Fund

0.74%

Family Office

0.04%

Bank and Trust

0.04%

Andere

43.25%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

180

38.60M

28.59%

-15.99M

2025Q2

187

92.52M

71.43%

-12.19M

2025Q1

188

90.99M

70.46%

-13.35M

2024Q4

184

92.39M

74.12%

+21.48M

2024Q3

176

90.75M

73.53%

+26.28M

2024Q2

216

81.85M

70.67%

+19.77M

2024Q1

231

37.73M

58.52%

-31.32M

2023Q4

239

39.92M

63.74%

-31.95M

2023Q3

236

64.28M

104.12%

-21.16M

2023Q2

223

59.02M

95.83%

-21.49M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Tolerantia LLC

22.62M

16.75%

--

Jun 03, 2025

Suvretta Capital Management, LLC

12.34M

9.14%

--

Jun 30, 2025

Control Empresarial de Capitales, S.A. de C.V.

10.72M

7.94%

+2.28M

+27.04%

Apr 22, 2025

Morgan Stanley Investment Management Inc. (US)

5.71M

4.23%

-4.33M

-43.14%

Jun 30, 2025

BlackRock Mexico Operadora SA de CV SOFI

3.43M

2.54%

--

Aug 31, 2025

Operadora de Fondos GBM S.A.B. de C.V.

2.45M

1.81%

--

Aug 31, 2025

Bleichroeder LP

2.00M

1.48%

--

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.72M

1.27%

-4.60M

-72.83%

Jun 30, 2025

The Vanguard Group, Inc.

1.57M

1.16%

-3.64M

-69.92%

Jun 30, 2025

Culleton (Bruce)

1.54M

1.14%

+1.54M

--

Mar 17, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Schwab U.S. Small-Cap ETF

0.01%

ALPS Medical Breakthroughs ETF

0%

Global X Russell 2000 Covered Call ETF

0%

Schwab U.S. Broad Market ETF

0%

ProShares UltraPro Russell2000

0%

ProShares Hedge Replication ETF

0%

iShares Russell 2000 ETF

0%

Avantis US Equity ETF

0%

Global X Russell 2000 ETF

0%

iShares Russell 2000 Growth ETF

0%

Schwab U.S. Small-Cap ETF

Anteil0.01%

ALPS Medical Breakthroughs ETF

Anteil0%

Global X Russell 2000 Covered Call ETF

Anteil0%

Schwab U.S. Broad Market ETF

Anteil0%

ProShares UltraPro Russell2000

Anteil0%

ProShares Hedge Replication ETF

Anteil0%

iShares Russell 2000 ETF

Anteil0%

Avantis US Equity ETF

Anteil0%

Global X Russell 2000 ETF

Anteil0%

iShares Russell 2000 Growth ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten